Market capitalization | $9.12m |
Enterprise Value | $6.57m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-21.44m |
Free Cash Flow (TTM) Free Cash Flow | $-16.70m |
Cash position | $3.53m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Mustang Bio, Inc.:
1 Analyst has issued a forecast Mustang Bio, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.46 -1.46 |
47%
47%
|
|
EBITDA | -20 -20 |
66%
66%
|
EBIT (Operating Income) EBIT | -21 -21 |
65%
65%
|
Net Profit | -23 -23 |
63%
63%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.
Head office | United States |
CEO | Manuel Litchman |
Employees | 80 |
Founded | 2015 |
Website | www.mustangbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.